ESC Congress Recap: High-Impact Clinical Trials, with Deepak Bhatt, MD, MPH, MBA
With 32,000 attendees from more than 170 countries, the European Society of Cardiology (ESC) Congress 2024 demonstrated how it has earned the reputation as 1 of the foremost scientific meetings in cardiology and medicine as a whole. Boasting 4,400 novel abstracts, including 112 studies simultaneously published in medical journals, the meeting served as a platform for debuting science and breakthroughs that could impact standards of care for cardiovascular disease management and prevention for decades.
A sequel to our ESC Congress preview, our editorial team sat down with Deepak Bhatt, MD, MPH, MBA, director of Mount Sinai Heart and the Dr. Valentin Foster Professor of Cardiovascular Medicine at the Icahn School of Medicine, for his post-conference perspective on the meeting’s top trials and new data releases. In the featured video, Bhatt highlights a group of 4 studies from the meeting: FINEARTS-HF, ABYSS, RESHAPE-HF2, and SHAM-PVI.
Source: MDMag
To view the third party content, kindly click on the link below or read more. You will then leave this site and enter a third party site.
